Coastline Trust Co Lowers Stock Holdings in Becton, Dickinson and Company $BDX

Coastline Trust Co lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 66.8% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,109 shares of the medical instruments supplier’s stock after selling 6,260 shares during the quarter. Coastline Trust Co’s holdings in Becton, Dickinson and Company were worth $536,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in BDX. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Becton, Dickinson and Company by 11.2% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 887,913 shares of the medical instruments supplier’s stock worth $152,943,000 after acquiring an additional 89,559 shares during the last quarter. Avior Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 2,934.1% in the 2nd quarter. Avior Wealth Management LLC now owns 7,919 shares of the medical instruments supplier’s stock worth $1,364,000 after purchasing an additional 7,658 shares in the last quarter. RBA Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 5.3% in the 2nd quarter. RBA Wealth Management LLC now owns 23,115 shares of the medical instruments supplier’s stock worth $3,982,000 after purchasing an additional 1,163 shares in the last quarter. Blossom Wealth Management grew its position in Becton, Dickinson and Company by 6.5% during the 2nd quarter. Blossom Wealth Management now owns 1,498 shares of the medical instruments supplier’s stock valued at $258,000 after purchasing an additional 92 shares during the last quarter. Finally, TOWER TRUST & INVESTMENT Co increased its stake in Becton, Dickinson and Company by 8.4% during the 2nd quarter. TOWER TRUST & INVESTMENT Co now owns 1,852 shares of the medical instruments supplier’s stock valued at $319,000 after purchasing an additional 143 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $184.59 on Friday. The firm has a market capitalization of $52.91 billion, a P/E ratio of 33.20, a PEG ratio of 1.49 and a beta of 0.27. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The business has a fifty day moving average of $188.27 and a 200 day moving average of $188.72.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Analysts Set New Price Targets

BDX has been the topic of several analyst reports. Argus upped their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $213.09.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,965 shares of company stock valued at $551,536 over the last 90 days. 0.36% of the stock is currently owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.